Epidermal Growth Factor (EGF): A Revolutionary Molecule from Basic Biology to Regenerative Medicine

Epidermal Growth Factor (EGF) is a milestone discovery in modern molecular biology and medicine. Its research history spans the entire second half of the twentieth century and continues to this day, fundamentally transforming our understanding of cell growth, differentiation, and tissue repair. As a potent promoter of cell division, EGF activates specific receptors on the cell surface, triggering a complex intracellular signaling network that ultimately directs cells to proliferate, migrate, survive, or differentiate. Since Stanley Cohen was awarded the 1986 Nobel Prize in Physiology or Medicine for his pioneering work on EGF, this small protein molecule has rapidly transitioned from a purely academic subject to a core focus of biotechnology and clinical therapeutic development. Its immense potential in wound healing, tissue engineering, cancer treatment, and even cosmetic skincare has brought boundless hope alongside profound challenges. This article delves into the discovery history, molecular mechanisms, physiological and pathological functions of EGF, as well as its widespread applications as a therapeutic drug and active ingredient in medical and cosmetic fields, the controversies it faces, and future directions.

 
The Discovery History and Basic Molecular Properties of EGF: A Nobel Prize-Winning Scientific Journey

The story of EGF's discovery began in the 1950s when Italian-American biologist Rita Levi-Montalcini observed a substance in mouse sarcoma tissue that significantly stimulated neuronal growth, known as Nerve Growth Factor (NGF). Inspired by this, her colleague Stanley Cohen began working to isolate and identify other factors with similar growth-stimulating activities. In a key experiment in 1962, Cohen identified a protein fraction in mouse submandibular gland extracts that caused newborn mice to open their eyes and grow teeth prematurely, a phenomenon resulting from its ability to accelerate epidermal tissue growth and maturation. He eventually successfully purified this substance and named it "Epidermal Growth Factor." This discovery not only revealed a new cell communication system but also laid the foundation for the field of growth factor research, earning the two scientists the shared 1986 Nobel Prize.

At the molecular level, human EGF is a short-chain polypeptide consisting of 53 amino acid residues, with a molecular weight of approximately 6 kilodaltons. Its three-dimensional structure is stabilized by three disulfide bonds (the most critical being Cys6-Cys20, Cys14-Cys31, and Cys33-Cys42), forming a compact globular structure essential for maintaining its biological activity. The EGF gene is located on human chromosome 4 (4q25), and its initial translation product is a large transmembrane precursor protein (proEGF) containing over 1,200 amino acids. This precursor protein not only serves as a storage form of EGF on the cell membrane but may also possess certain biological functions itself. After cleavage by specific proteolytic enzymes (such as metalloproteinases), the mature EGF fragment is released to act on surrounding or its cells in a paracrine or autocrine manner. This complex generation and regulation mechanism ensures precise spatiotemporal control of EGF signaling, preventing uncontrolled activity and adverse consequences.
 
Q : What Is the Signaling Mechanism of EGF?
The core of EGF's function lies in its precise binding to specific receptors on the cell membrane—Epidermal Growth Factor Receptors (EGFR, also known as ErbB1 or HER1). EGFR is one of the four members of the ErbB receptor tyrosine kinase (RTK) family, featuring a ligand-binding extracellular domain, a transmembrane domain, and an intracellular domain with tyrosine kinase activity. In the absence of EGF, EGFR exists primarily as monomers with low activity. Once an EGF molecule binds to an EGFR monomer, it induces a conformational change in the receptor, exposing a dimerization interface that enables it to form homodimers or heterodimers with another EGFR monomer or other family members (such as HER2).

Dimer formation is a critical step in activating signaling. It leads to the mutual phosphorylation of specific tyrosine residues in the intracellular domains of the two receptors by their tyrosine kinases. This autophosphorylation process ignites the signaling fuse, creating multiple docking sites in the intracellular domain that recruit a plethora of downstream signaling proteins. These proteins, equipped with SH2 or PTB domains, recognize and bind to the phosphorylated tyrosines. Consequently, a series of complex signaling pathways are rapidly activated:includes the RAS-RAF-MEK-ERK (MAPK/ERK) pathway (Dominant cell proliferation and differentiation), the PI3K-AKT-mTOR pathway (主导 cell survival and metabolism), and the JAK-STAT pathway (主导 gene transcription regulation). These signaling cascades ultimately converge in the cell nucleus, regulating the expression of key genes such as Cyclin D1 and c-Myc, driving the cell from the G1 phase to the S phase, and initiating DNA synthesis and cell division. The entire signaling process is not linear but a dynamic network filled with feedback regulation, crosstalk, and signal attenuation mechanisms. The strength and duration of the signal determine the cell's ultimate fate—sustained proliferation, differentiation, or apoptosis.
 
Q : What Roles Does EGF Play in Physiological and Pathological Processes?
Under normal physiological conditions, EGF is an indispensable guardian for maintaining tissue homeostasis and completing repair tasks. It is produced by various cells, including keratinocytes, platelets, macrophages, and glandular cells such as those in the salivary glands and duodenal glands. Its main physiological functions include: Promoting epithelial cell proliferation: Continuously replenishing cell loss in epithelial tissues such as the skin, cornea, gastrointestinal tract, and respiratory tract, maintaining their barrier integrity. Accelerating wound healing: After tissue injury, EGF released by platelets serves as the initial signal for the repair process, attracting inflammatory cells to clear debris and strongly stimulating fibroblast and keratinocyte proliferation and migration, forming granulation tissue and completing re-epithelialization. Regulating developmental processes: During the embryonic stage, the expression of EGF and its receptor plays a key guiding role in the normal morphogenesis and functional maturation of various organs (such as the lungs, kidneys, and skin).

However, when the EGF/EGFR signaling pathway becomes abnormally hyperactive, this loyal guardian can transform into a dangerous rebel, becoming a core driver of tumor initiation and development. Extensive research has shown that dysregulation of the EGFR signaling pathway is closely associated with various epithelial-derived malignancies (such as non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, glioblastoma, etc.). The pathogenic mechanisms are diverse: including gene mutations in the receptor itself (leading to its sustained activation without ligand binding), gene amplification (resulting in an abnormal increase in the number of receptors on the cell surface), excessive ligand production (autocrine or paracrine production of excessive EGF-like molecules by tumor cells or cells in the tumor microenvironment), and mutations in downstream signaling proteins (such as RAS and BRAF mutations). This persistent, intense mitogenic signal drives cancer cells to proliferate indefinitely, resist apoptosis, promote angiogenesis, and enhance invasive and metastatic capabilities. Therefore, EGFR has become one of the most important and successful targets in cancer targeted therapy.
 
Clinical Applications of EGF: From Regenerative Medicine to the Anti-Cancer Battlefield
Leveraging its powerful biological functions, EGF has been developed into various therapeutic products widely used in clinical practice. In the field of wound repair, recombinant human EGF (rhEGF) topical ointments, gels, or sprays have become effective means for treating refractory wounds such as diabetic foot ulcers, pressure sores, burns, and skin graft donor sites. They act directly on the wound, stimulating granulation tissue growth and epithelial migration, significantly shortening healing time, reducing infection risk, and minimizing scar formation. In ophthalmology, EGF-containing eye drops are used to treat corneal epithelial injuries, chemical burns, and to promote corneal repair after refractive surgery. In gastroenterology, oral EGF preparations have even been explored for treating peptic ulcers, aiming to enhance the repair capacity of the gastrointestinal mucosa against damaging factors.

On the other hand, anti-cancer therapies targeting the aberrant activation of the EGF pathway have achieved even more remarkable success, ushering in a new era of targeted cancer therapy. These drugs are mainly divided into two categories: First, anti-EGFR monoclonal antibodies, such as Cetuximab and Panitumumab. They bind directly to the extracellular domain of EGFR, competitively blocking EGF binding, and inducing receptor internalization and degradation, thereby inhibiting downstream signaling. They are primarily used to treat RAS wild-type metastatic colorectal cancer and head and neck squamous cell carcinoma. Second, small molecule tyrosine kinase inhibitors (TKIs), such as Gefitinib, Erlotinib, and Osimertinib. These drugs can penetrate the cell membrane and bind directly to the kinase domain in the intracellular region of EGFR, inhibiting its phosphorylation activity. They are particularly effective for non-small cell lung cancer patients with specific activating mutations, achieving a leap from "indiscriminate killing by chemotherapy" to "precision targeted strikes." However, the emergence of drug resistance remains the biggest challenge currently faced.
 
Beyond Therapy: The Application and Controversy of EGF in Cosmetics
EGF's powerful ability to promote cell regeneration has naturally attracted significant interest from the cosmetics industry. In recent years, "EGF skincare" has become a major trend in the high-end skincare market, claiming miraculous effects such as anti-aging, wrinkle removal, skin barrier repair, and scar fading. The theoretical basis is that exogenous supplementation of EGF can activate stem cells in the epidermal basal layer and senescent fibroblasts, promoting the synthesis of collagen, elastin, and hyaluronic acid, thereby increasing skin thickness, improving wrinkles, and enhancing elasticity and hydration.

However, the use of EGF in cosmetics has sparked significant scientific and regulatory controversy. Efficacy controversy: The stratum corneum of healthy skin is a difficult barrier to penetrate, and whether large EGF molecules (>4000 daltons) can effectively penetrate the skin and reach their target cells in the basal layer is a critical technical bottleneck. Even if they can enter, the activity and stability of exogenous EGF in the complex skin microenvironment are questionable. Safety controversy: A more serious concern is its potential tumor-promoting risk. Although topical application carries a different risk profile compared to systemic administration, for skin with pre-existing precancerous lesions or microtumors (especially in the elderly), the long-term, heavy use of potent growth factors may "nourish" these abnormal cells and accelerate tumor development, a theoretical risk that cannot currently be exclude. Therefore, drug regulatory agencies in many countries and regions (such as China's NMPA) have explicitly listed EGF (often referred to as "human oligopeptide-1" in cosmetics) as a prohibited component in cosmetics, allowing it only as a strictly regulated drug. Many products on the market actually add functionally similar "peptides" or "Oligopeptide" rather than genuine EGF, and their claimed "EGF efficacy" is often misleading.
 
Future Prospects and Challenges
Looking ahead, EGF research will continue to develop in depth. At the basic research level, scientists are committed to more precisely parse the dynamic regulation and feedback mechanisms of the EGFR signaling network and its interactions with other signaling pathways, hoping to discover new regulatory nodes. In the therapeutic field, the future focus will be on overcoming resistance to targeted drugs, for example, by developing new-generation irreversible inhibitors, bispecific antibodies, and combination therapy strategies such as combining EGFR inhibitors with immune checkpoint inhibitors (e.g., PD-1/PD-L1 antibodies). In the field of regenerative medicine, research is trending towards combining EGF with other growth factors (such as FGF, PDGF) or biomaterials (such as hydrogels, scaffolds) to construct intelligent controlled-release systems that enable precise spatiotemporal delivery of growth factors, maximizing repair effects while minimizing side effects. Finally, for cosmetic applications, establishing strict standards, reliable transdermal technologies, and comprehensive long-term safety assessment systems are essential steps for the industry to move towards scientific and standardized practices.

In conclusion, Epidermal Growth Factor has evolved from a simple biological discovery into a powerful paradigm connecting basic science, medical therapy, and commercial application. It demonstrates both the exquisite sophistication of life processes and the complexity and responsibility involved in translating scientific achievements into practice. Continued in-depth research on EGF will undoubtedly bring revolutionary impacts to human health and quality of life.
 
Click on the product catalog numbers below to access detailed information on our official website.
 
Product Information

UA040400	HB-EGF Protein, Rat	Host : Rat Expression System : E.coli Conjugation : Unconjugated
UA040126	EGF Protein, Mouse	Host : Mouse Expression System : E.coli Conjugation : Unconjugated
UA040228	EGF Protein, Rat	Host : Rat Expression System : E.coli Conjugation : Unconjugated
UA040252	HB-EGF Protein, Mouse	Host : Mouse Expression System : E.coli Conjugation : Unconjugated

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.